Seeking Alpha

More on Regeneron's (REGN) Q1 : The company exhibits "sustained revenue and earnings growth"...

More on Regeneron's (REGN) Q1 : The company exhibits "sustained revenue and earnings growth" helped by strong EYLEA sales growth in the U.S. (FY13 U.S. sales estimates for the macular degeneration injection hiked to $1.25-1.325B) and a healthy roll out of the drug outside the country by partner Bayer Healthcare. Late stage pipeline makes progress. Shares +5% premarket. ( PR )
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)